Glycotope Presents Glyco-Engineered Cell Lines at GlycoBioTec 2023 – 3rd International GlycoBioTec Symposium

Berlin, Germany, 17 January, 2023 – Glycotope GmbH, a biotechnology company with a proprietary platform technology for developing antibodies against proteins carrying tumor-specific carbohydrate structures, today announces that it will present its glyco-engineered cell lines at GlycoBioTec 2023 – 3rd International GlycoBioTec Symposium, being held in Berlin, Germany, on 17 and 18 January 2023.

Patrik Kehler, Chief Scientific Officer of Glycotope GmbH commented: “Our glyco-engineered cell lines provide the basis for the generation of therapeutic antibodies with increased tumor specificity and safety for highly potent therapeutic approaches like ADCs, CARs and radiotherapeutics. It represents a versatile tool for target validation and screening of glycosylation-dependent protein binding antibodies. It is great, that our scientists have the opportunity to present their work at GlycoBioTec 2023 and to discuss with other glycobiotechnology experts.”

Poster details are as follows:

Abstract: Download here 

Title: Using glyco-engineered cells with flexible expression of tumor-associated carbohydrates for the generation of highly tumor-specific antibodies

Poster Presentation: 17 January 2023, 6:00am – 7:00pm CET

Contact Information:

Glycotope GmbH

Dr. Patrik Kehler (CSO)

Phone: +49 30 9489 2600

Email: contact@glycotope.com

About Glycotope

Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies. Our antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GlycoTargets). Glycotope has to date discovered in excess of 200 GlycoTargets with antibodies against several of these targets currently under development.

Based on their superior tumor-specificity, our antibodies are suitable for development in an array of different modes of action including naked antibodies, bispecifics, antibody-drug-conjugates, cellular therapies or fusion-proteins. Visit www.glycotope.com